RP9 siRNA (h): sc-89416



The Power to Question

BACKGROUND

RP9 (retinitis pigmentosa 9 protein), also known as Pim-1 kinase associated protein or PAP-1, is a 221 amino acid nuclear protein that associates with Pim-1 to influence B-cell proliferation. Expressed in a multitude of tissues, RP9 may also be the target protein for Pim-1 kinase. The gene encoding RP9 maps to human chromosome 7, which, when defective, is the cause of a disorder known as retinitis pigmentosa type 9 (RP9). Patients with retinitis pigmentosa 9 experience degeneration of retinal photoreceptor cells. Chromosome 7 houses over 1,000 genes, comprises nearly 5% of the human genome and has been linked to osteogenesis imperfecta, Pendred syndrome, lissencephaly, citrullinemia and Shwachman-Diamond syndrome.

REFERENCES

- 1. Tsipouras, P., Myers, J.C., Ramirez, F. and Prockop, D.J. 1983. Restriction fragment length polymorphism associated with the pro α 2l gene of human type I procollagen. Application to a family with an autosomal dominant form of osteogenesis imperfecta. J. Clin. Invest. 72: 1262-1267.
- 2. Liang, H., Fairman, J., Claxton, D.F., Nowell, P.C., Green, E.D. and Nagarajan, L. 1998. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. Proc. Natl. Acad. Sci. USA 95: 3781-3785.
- 3. Iwasaki, S., Usami, S., Abe, S., Isoda, H., Watanabe, T. and Hoshino, T. 2001. Long-term audiological feature in Pendred syndrome caused by PDS mutation. Arch. Otolaryngol. Head Neck Surg. 127: 705-708.
- Keen, T.J., Hims, M.M., McKie, A.B., Moore, A.T., Doran, R.M., Mackey, D.A., Mansfield, D.C., Mueller, R.F., Bhattacharya, S.S., Bird, A.C., Markham, A.F. and Inglehearn, C.F. 2002. Mutations in a protein target of the Pim-1 kinase associated with the RP9 form of autosomal dominant retinitis pigmentosa. Eur. J. Hum. Genet. 10: 245-249.
- Osborne, L.R., Joseph-George, A.M. and Scherer, S.W. 2006. Williams-Beuren syndrome diagnosis using fluorescence *in situ* hybridization. Methods Mol. Med. 126: 113-128.
- 6. Reiner, O., Sapoznik, S. and Sapir, T. 2006. Lissencephaly 1 linking to multiple diseases: mental retardation, neurodegeneration, schizophrenia, male sterility, and more. Neuromolecular Med. 8: 547-565.
- Gilbert-Dussardier, B. 2006. Williams-Beuren syndrome. Rev Prat. 56: 2102-2106.
- Leone, G., Pagano, L., Ben-Yehuda, D. and Voso, M.T. 2007. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92: 1389-1398.

CHROMOSOMAL LOCATION

Genetic locus: RP9 (human) mapping to 7p14.3.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

PRODUCT

RP9 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see RP9 shRNA Plasmid (h): sc-89416-SH and RP9 shRNA (h) Lentiviral Particles: sc-89416-V as alternate gene silencing products.

For independent verification of RP9 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-89416A, sc-89416B and sc-89416C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

 $\ensuremath{\mathsf{RP9}}\xspace$ siRNA (h) is recommended for the inhibition of RP9 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor RP9 gene expression knockdown using RT-PCR Primer: RP9 (h)-PR: sc-89416-PR (20 μ I). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com